Keyword: Supernus

Supernus’ two phase 3 studies in children with ADHD hit their primary endpoints but didn’t wow investors worried about established generics.

Supernus makes a return to epilepsy R&D, buying the developer of a traditional Chinese medicine-derived drug for $15 million upfront.

Specialty pharma Supernus has posted positive data from its childhood ADHD midstage test as it looks to start Phase III trials next year--but its shares ticked down as some decided to “sell the news” instead of buying into it.